Benzofuroxan Pharma Grade API is a crystalline non-compendial active pharmaceutical ingredient supplied for solid oral dosage-form manufacture and, when the injectable designation is requested, for sterile parenteral processing. Chemical identity is 2,1,3-benzoxadiazole 1-oxide, CAS Registry Number 480-96-6, molecular formula C6H4N2O2, molecular weight 136.11 g/mol. Manufacturer-defined model designations distinguish the oral grade, identified as BZF-PG-O, from the injectable grade, identified as BZF-PG-I; a milled or micronised variant for low-dose dry blending or suspension processing is identified as BZF-PG-M. These model codes are supplier-specific and must be mapped to the chemistry, manufacturing, and controls dossier. The N-oxide function is the structural driver that separates benzofuroxan from benzofurazan and introduces redox participation in both degradation and possible biotransformation. Because no dedicated USP–NF or Ph. Eur. monograph currently assigns all release controls, the API is governed by ICH Q6A for non-compendial materials, with residual solvents by ICH Q3C, elemental impurities by ICH Q3D, and good manufacturing practice by ICH Q7 and FDA 21 CFR 210/211. The intended dosage forms—tablet, capsule, granule, oral and injectable—require different physical and microbial attributes, but the chemical purity backbone remains common.

Which release specifications separate the oral grade from the injectable grade?

The separation is determined by the bioburden, bacterial endotoxin, and subvisible particulate test package, not by a different chemical identity. Assay and related-substance targets are shared, but injectable-grade material is released under tighter microbial and drying controls because it bypasses many terminal sterilisation options. The table below presents representative release controls for a non-compendial API in the absence of a public monograph; the values are design thresholds drawn from typical pharmaceutical API specifications and must be confirmed against the licensed dossier.

Particle-size limits are not universal for benzofuroxan; they are assigned during formulation development and are not a substitute for blend uniformity or dissolution testing.

Direct compression of benzofuroxan-containing blends depends on particle-size control measured by laser diffraction per ISO 13320:2020. Coarse crystalline lots with D90 above 250 µm usually produce segregation in tumble blenders and weight variation on high-speed rotary tablet presses; jet-milled or pin-milled material with D90 below 100 µm improves content uniformity but can reduce flow and increase dust. Flow is assessed by bulk and tapped density according to USP <616> and by flow through a 10 mm orifice according to USP <1174>; a Hausner ratio above 1.35 typically signals the need for roller compaction or wet granulation. For capsules, the granulate or direct blend is filled on dosator or tamping-pin machines; fill weight variability should be below ±3% relative standard deviation for development batches and below ±5% for early feasibility batches. Blend uniformity is assessed by USP <905>; dissolution is conducted in a validated medium under USP <711>. For wet granulation, binder selection follows pH-solubility profiling of the API; if solubility is low in purified water, a low-viscosity binder such as pregelatinised starch or hypromellose can be screened. High-shear granulator end point is controlled by impeller torque and chopper speed rather than fixed time; the N-oxide group can undergo redox side reactions at elevated temperature, so fluid-bed inlet air is maintained below 40 °C until forced degradation data support higher exposure. Dry granulation via a roller compactor is an alternative; ribbon solid fraction is measured by pycnometry or dimensional density, and the flakes are milled to a defined sieve size to reduce fines.

Scale-up from laboratory to production for benzofuroxan tablets should not be based solely on blend potency. The API’s cohesive fraction and static charge after micronisation may cause sticking to tablet punch faces. Process parameters to transfer include compression force, pre-compression force, turret speed, and die-fill depth. In high-speed rotary tablet presses, turret speeds above 60 rpm can increase die-fill variation if the blend has a bulk density below 0.45 g/mL. Lubrication with magnesium stearate should be limited to 0.5–1.0% and a blending time below 5 min to avoid excessive hydrophobicity and dissolution slowdown. For capsules, addition of 0.5–1.0% colloidal silicon dioxide may improve flow; excess glidant can reduce granule wettability. These values are general solid-oral development parameters; benzofuroxan-specific stability data must confirm compatibility.

When Benzofuroxan is processed for parenteral use, what additional controls are required?

Injectable-grade benzofuroxan is not simply oral-grade powder with lower endotoxin; it requires a controlled microbial and particulate supply chain. Dispensing and sub-batching for sterile products should occur in an ISO 14644-1 Class 5 environment or in a restricted access barrier system with validated airflow, while oral processing can be conducted in Class 8 or equivalent controlled non-classified areas. If the dosage form is a solution, the API must dissolve completely in the selected solvent system without visible particles; filtration through a 0.22 µm sterilising membrane is used after API dissolution. If the product is a suspension or requires aseptic powder filling, particle-size distribution and container-closure integrity become critical. Endotoxin reduction by depyrogenation of API is generally not performed at the drug-product stage; therefore the injectable grade must meet the ≤0.25 EU/mg limit before release. Terminal steam sterilisation of a benzofuroxan solution is not assumed to be acceptable because the N-oxide group may undergo thermal reduction or rearrangement; terminal sterilisation may be considered only after forced degradation studies per ICH Q1A show acceptable assay and related-substances retention. Aseptic filtration is the preferred sterilising process. Filter compatibility studies should include filter type, lot, pressure differential, and post-filtration assay because adsorptive loss of a low-dose hydrophobic API can alter potency. For lyophilised formulations, the glass transition temperature of the frozen matrix must be determined; primary drying is conducted below the collapse temperature, not at a fixed product temperature.

Orthogonal identity testing is required because no dedicated monograph exists. Infrared absorption spectrophotometry per Ph. Eur. 2.2.24 and HPLC retention time relative to a qualified reference standard provide primary identification; X-ray powder diffraction per Ph. Eur. 2.9.33 is used when crystal form is stability-relevant. Assay and related substances are typically determined by reversed-phase HPLC with ultraviolet detection, using column temperature controlled at 25 °C or 30 °C and a mobile phase selected to resolve benzofuroxan from benzofurazan and opened-ring degradation products. The impurity profile should be forced through acid, base, oxidative, thermal, and photolytic stress according to ICH Q1A; oxidative conditions are especially informative for the N-oxide group. Liquid chromatography–mass spectrometry or high-resolution mass spectrometry is used to assign structures to degradation products above the identification threshold. Residual solvent analysis uses headspace gas chromatography with flame ionisation detection after dissolution in a suitable solvent; dimethyl sulfoxide should be avoided if it forms adducts or broadens early eluting peaks. Elemental impurity data should be collected by inductively coupled plasma mass spectrometry after acid microwave digestion. For injectable grade, particulate matter in the final product must meet USP <788> or Ph. Eur. 2.9.19, and bacterial endotoxin must be measured with a compendial limulus amebocyte lysate method. Published data for benzofuroxan-specific forced degradation profiles is limited; therefore each site should generate its own impurity map before validation.

Benzofurazan and nitroarene N-oxide differentiation in preformulation

Benzofuroxan is differentiated from benzofurazan by the exocyclic N-oxide oxygen. The N-oxide function increases molecular polarity, modifies chromatographic retention, and introduces redox reactions not observed for benzofurazan. This distinction is relevant when comparing API grades or when designing impurity controls: benzofurazan may be a reduction product or synthetic precursor, so HPLC resolution between benzofuroxan and benzofurazan should be part of the system suitability test. Unlike nitroarene nitric-oxide donors, benzofuroxan does not contain a classical nitro group; pharmacological activity is not determined solely by nitric-oxide release and must not be inferred from other donor classes without impurity and metabolite data. In solid-state preformulation, the N-oxide group can participate in hydrogen bonding and may alter hygroscopicity and compaction properties relative to unoxidised heterocycles. The following table compares the two related compounds and a generic nitroarene donor class; because clinical relevance is molecule-specific, the table is oriented to analytical and formulation behaviour rather than therapeutic equivalence.

Manufacturing incompatibilities are concentrated at the N-oxide. Benzofuroxan should not be dry-blended with strong reducing agents such as ascorbic acid, sodium metabisulfite, or sulfhydryl-containing excipients unless compatibility studies demonstrate control of reduction products. Transition-metal ions, especially iron and copper, should be excluded from contact surfaces and process water because they can catalyse redox degradation. Strong bases and prolonged alkaline pH can open the oxadiazole ring; pH excursions during granulation or injection compounding should be limited by buffer selection and mixing time. For tablet film-coating operations, aqueous coating at 50–60 °C is common for general APIs, but benzofuroxan tablets should be coated only after core stability at the selected pan temperature is verified. Packaging for solid oral forms requires light-protective barrier materials if photostability per ICH Q1B shows sensitivity; glass or aluminium foil blisters are preferred over polyethylene containers when low oxygen permeability is required. For injectable grade, contact with silicone tubing during filtration or filling should be evaluated for extractables and adsorptive loss because low-solubility APIs can partition to silicone surfaces.

Environmental controls in dispensing and packaging of oral and injectable grades

At incoming quality control, identity, assay, water content, particle size, and residual solvents are repeated per the site master plan. Oral-grade dispensing should occur in a humidity-controlled area with relative humidity maintained below 60%; if the API is exposed above this threshold, loss on drying should be rechecked before weighing. Injectable-grade dispensing shifts to a classified ISO 14644-1 Class 5 area or an isolator with automatic particle monitoring. Bulk packaging for oral grade is typically double low-density-polyethylene liners inside a fibre drum; injectable grade is packaged in sterile, low-particulate containers with closure integrity and bioburden control. Transport containers should be sealed with tamper-evident closures. Temperature during transport and storage is controlled at 15–25 °C unless the manufacturer’s stability programme supports wider excursion. Avoid storage near reducing agents, oxidising acids, or direct sunlight. Any deviation in moisture content outside release limits should trigger quarantine and blend revalidation, because water activity at the granulation stage affects degradation kinetics and compaction reproducibility.